(2S,4R)-4-(2-(trifluoromethyl)phenoxy)pyrrolidine | 921606-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,4R)-4-(2-(trifluoromethyl)phenoxy)pyrrolidine
• 英文别名: (3R)-3-[2-(trifluoromethyl)phenoxy]pyrrolidine
• CAS: 921606-29-3
• 化学式: C₁₁H₁₂F₃NO
• 分子量: 231.218
• InChiKey: XNRDRGOBJOHKEX-MRVPVSSYSA-N

物化性质

• 沸点：
  282.4±40.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,4R)-4-(2-(trifluoromethyl)phenoxy)pyrrolidine 、 4-氯-6,7-二甲氧基喹唑啉 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 27.0h， 以24 mg的产率得到6,7-dimethoxy-4-[(3R)-3-[2-(trifluoromethyl)phenoxy]pyrrolidin-1-yl]quinazoline
  参考文献：
  名称：

  Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitors

  摘要：

  A papaverine based pharmacophore model for PDE10A inhibition was generated via SBDD and used to design a library of 4-amino-6,7-dimethoxyquinazolines. From this library emerged an aryl ether pyrrolidyl 6,7-dimethoxyquinazoline series that became the focal point for additional modeling, X-ray, and synthetic efforts toward increasing PDE10A inhibitory potency and selectivity versus PDE3A/B. These efforts culminated in the discovery of 29, a potent and selective brain penetrable inhibitor of PDE10A.

  DOI：

  10.1021/jm060653b
• 作为产物：
  描述：

  邻三氟甲基苯酚 在 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 (2S,4R)-4-(2-(trifluoromethyl)phenoxy)pyrrolidine
  参考文献：
  名称：

  Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitors

  摘要：

  A papaverine based pharmacophore model for PDE10A inhibition was generated via SBDD and used to design a library of 4-amino-6,7-dimethoxyquinazolines. From this library emerged an aryl ether pyrrolidyl 6,7-dimethoxyquinazoline series that became the focal point for additional modeling, X-ray, and synthetic efforts toward increasing PDE10A inhibitory potency and selectivity versus PDE3A/B. These efforts culminated in the discovery of 29, a potent and selective brain penetrable inhibitor of PDE10A.

  DOI：

  10.1021/jm060653b

文献信息

• [EN] NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS<br/>[FR] NOUVEAUX PHÉNYL IMIDAZOLES ET PHÉNYL TRIAZOLES EN TANT QUE MODULATEURS DE LA GAMMA SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2010100606A1

  公开（公告）日：2010-09-10

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有规范中定义的Formula (I)的结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。
• SuFEx Activation with Ca(NTf₂)₂: A Unified Strategy to Access Sulfamides, Sulfamates, and Sulfonamides from S(VI) Fluorides
  作者：Subham Mahapatra、Cristian P. Woroch、Todd W. Butler、Sabrina N. Carneiro、Sabrina C. Kwan、Samuel R. Khasnavis、Junha Gu、Jason K. Dutra、Beth C. Vetelino、Justin Bellenger、Christopher W. am Ende、Nicholas D. Ball

  DOI：10.1021/acs.orglett.0c01397

  日期：2020.6.5

  A method to activate sulfamoyl fluorides, fluorosulfates, and sulfonyl fluorides with calcium triflimide and DABCO for SuFEx with amines is described. The reaction was applied to a diverse set of sulfamides, sulfamates, and sulfonamides at room temperature under mild conditions. Additionally, we highlight this transformation to parallel medicinal chemistry to generate a broad array of nitrogen-based

  描述了用三氟甲磺酸钙和DABCO活化胺磺酰氟，氟硫酸盐和磺酰氟的方法，用于胺与SuFEx。在室温和温和条件下，将反应物应用于各种不同的磺酰胺，氨基磺酸盐和磺酰胺。此外，我们强调了这种向平行药物化学的转化，以生成各种基于氮的S（VI）化合物。
• Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
  申请人：Allen Martin Patrick

  公开号：US20120053165A1

  公开（公告）日：2012-03-01

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了具有式（I）所定义的结构的化合物及其药学上可接受的盐，同时公开了相应的制药组合物、治疗方法、合成方法和中间体。
• SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors
  作者：Yeeman K. Ramtohul、Cameron Black、Chi-Chung Chan、Sheldon Crane、Jocelyne Guay、Sébastien Guiral、Zheng Huang、Renata Oballa、Li-Jing Xu、Lei Zhang、Chun Sing Li

  DOI：10.1016/j.bmcl.2010.01.083

  日期：2010.3

  Elevated stearoyl-CoA desaturase (SCD) activity has been linked to a number of metabolic disorders including obesity and type II diabetes. Compound 3j, a potent SCD inhibitor (human HepG2 IC(50) = 1 nM) was identified from the optimization of a lead thiazole compound MF-152 with over 100-fold improvement in potency. In a 4-week chronic oral dosing at 0.2 mg/ kg, 3j gave a robust 24% prevention of body weight gain in mice fed on a high fat diet accompanied with an improved metabolic profile on insulin and glucose levels. (C) 2010 Elsevier Ltd. All rights reserved.